February 2019 Shareholder Newsletter
Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors.
Read More
Dr Alan Olivero discusses what makes a good brain cancer drug
Dr Alan Olivero, who led the team at Genentech that developed GDC-0084, discusses what makes a good brain cancer drug.
Read More
Proactive Investors speaks with Kazia CEO Dr James Garner
Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.
Read More
2018 Annual General Meeting Presentation Webcast
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2018 AGM, together with questions and answers relating to the presentation.
Read More
November 2018 Shareholder Newsletter
Kazia Therapeutics is pleased to make its November 2018 newsletter available.
Read More
Morgans interview with Kazia CEO Dr James Garner
Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.
Read More
Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience
Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.
Read More
Kazia enters clinical collaboration to study use of brain cancer drug GDC-0084 in breast cancer
The Australian oncology-focused biotech Kazia Therapeutics announced today that it will collaborate with world-leading treatment and research centre Dana-Farber Cancer Institute to investigate the use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain.
Read More
Australian clinical trial of ovarian cancer therapy Cantrixil pivotal for cancer stem cell research
The Australian phase 1 clinical trial of the drug Cantrixil for recurrent ovarian cancer could shape the next wave of clinical research into drugs targeting cancer stem cells, a peer-reviewed paper published in Expert Opinion on Orphan Drugs this month has found.
Read More
Sydney Shareholder Information Session July 2018
Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.
Read More
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked